However, based on observations for other targeted therapies (EGFR, BRAF, KIT) for various cancers, including colon and lung cancers, melanoma, and gastrointestinal tumors, FGFR3‐targeted therapies will probably turn out to be limited by multiple mechanisms of intrinsic and acquired resistance, such as ERBB2/3 or EGFR activation (Flaherty et al, 2012; Herrera‐Abreu et al, 2013; Niederst & Engelman, 2013; Wang et al, 2015). This evidence concerns the gene EGFR and lung cancer.